Novartis pauses rap-cel trials after deaths
Analysis based on 7 articles · First reported Sep 01, 2026 · Last updated Sep 04, 2026
The trial pause raises safety concerns for CAR-T therapies in autoimmune indications, potentially affecting the development timelines and market prospects for Novartis and Bristol Myers Squibb. However, Novartis shares rose 4% as investors prioritized the positive late-stage data for Remibrutinib, indicating the market views the halt as manageable.
On August 24, 2026, Novartis paused eight clinical trials of its experimental CAR-T cell therapy Rap cell after three patients died from severe, life-threatening immune reactions. The trials targeted autoimmune and neurological disorders including lupus, rheumatoid arthritis, vasculitis, multiple sclerosis, and myasthenia gravis. Novartis is conducting a comprehensive review with independent safety boards and is sharing information with health authorities. Two trials for lymphoma and leukemia were unaffected. Bristol Myers Squibb also voluntarily paused studies of its rival CAR T cell Zola-cel as a precaution. Despite the halt, Novartis shares rose 4% on September 1 as investors focused on the late-stage success of its oral multiple sclerosis drug Remibrutinib.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard